Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01655316|
Recruitment Status : Completed
First Posted : August 1, 2012
Last Update Posted : November 14, 2012
PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases.
Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent.
Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising.
This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.
|Condition or disease||Intervention/treatment||Phase|
|Paroxysmal Supraventricular Tachycardia||Drug: Verapamil||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||August 2011|
U.S. FDA Resources
40 mg Verapamil Per Oral
- Recurrence Control [ Time Frame: 2 hours ]